At the intersection of science, innovation, and healthcare, Abu Dhabi Biobank enables the next generation of discoveries through world-class biobanking, biospecimen management, and translational research support. With deep expertise in building, operating, and optimizing biobank infrastructures, we empower pharma, biotech, government, and academic institutions to access high-quality human samples, data integration, and regulatory-compliant services that accelerate research and clinical breakthroughs.
From sample collection and storage to global logistics, bioinformatics, and clinical trial support, our solutions fuel discovery, validate therapies, and advance personalized medicine at scale.
We establish and operationalize national biobanks for governments and institutional facilities through Build-Operate-Transfer (BOT) models, ensuring every biospecimen— whether blood, tissue, saliva or other samples —is preserved with uncompromising quality. Alongside infrastructure, we provide training, education, and awareness program support that safeguard sample integrity, setting the foundation for impactful research.
We support with setting up a population-based biomedical resource by collecting biological samples for studies, archival services for existing sample storages that have outgrown their existing space and integrating them with advanced health metadata—including genomic, phenotypic, environmental, and electronic medical records to support prevention, diagnosis, treatment development, and policy innovation.
With global cold-chain logistics, we make biospecimens accessible anywhere in the world. From disease-nested cohorts to transplant-grade and HLA-typed samples, we deliver with precision and reliability. For pharma and academia, we design custom cohorts aligned with clinical trial pipelines, while our public registry aids transplants globally, to enhance patient care via future personalized medicine applications.
Our R&D services support every stage of translational research—from biomarker discovery and validation pipelines to advanced molecular assays, sequencing, and genotyping. With histopathology, digital pathology, and innovations such as organoid and Induced Pluripotent Stem Cell (iPSC) development, we enable both discovery and validation.
Our consultancy and advisory support ensure partners align with global biobanking standards. Research requests are integrated into Abu Dhabi’s Trusted Research Environment (TRE) for secure and ethical research access to drive public health advancement through regionally relevant research.
Every biospecimen is paired with powerful insights. By integrating clinical, demographic, and lifestyle data, we give researchers a 360-degree view of patient populations. Secure, de-identified databases are available through subscription or project-based access, enabling hypothesis generation and accelerating drug development through curated analytics. Our expertise propels partners to be at the forefront of a transformative effort that aligns with their strategic vision for a healthier, research-driven future for all.
We enable smarter, faster trials through patient stratification, pre-screening, and retrospective or prospective cohort design. Leveraging pan-human biospecimens, we help validate trial outcomes while advancing personalized medicine through companion diagnostic development in close collaboration with pharma partners. Our M42 network includes IROS, a UAE based CRO (Clinical Research Organization) with unparalleled access to cutting-edge scientific services and resources.
We aim to provide comprehensive and precise clinical solutions to drive healthcare and medical research excellence, focusing on real-world and clinical trial-backed evidence across all domains.
Trust is built on compliance. From informed consent management and donor engagement to advisory support for regulations like AABB, ISO, and EBAA submissions and others, we provide end-to-end ethical and regulatory guidance. Our expertise ensures international compliance, covering approvals, Material Transfer Agreements (MTAs), and legal frameworks with precision.
Our team of regulatory, legal and compliance experts helps clients contribute to global biomedical discovery and innovation.
We establish and operationalize national biobanks for governments and institutional facilities through Build-Operate-Transfer (BOT) models, ensuring every biospecimen— whether blood, tissue, saliva or other samples —is preserved with uncompromising quality. Alongside infrastructure, we provide training, education, and awareness program support that safeguard sample integrity, setting the foundation for impactful research.
We support with setting up a population-based biomedical resource by collecting biological samples for studies, archival services for existing sample storages that have outgrown their existing space and integrating them with advanced health metadata—including genomic, phenotypic, environmental, and electronic medical records to support prevention, diagnosis, treatment development, and policy innovation.
With global cold-chain logistics, we make biospecimens accessible anywhere in the world. From disease-nested cohorts to transplant-grade and HLA-typed samples, we deliver with precision and reliability. For pharma and academia, we design custom cohorts aligned with clinical trial pipelines, while our public registry aids transplants globally, to enhance patient care via future personalized medicine applications.
Our R&D services support every stage of translational research—from biomarker discovery and validation pipelines to advanced molecular assays, sequencing, and genotyping. With histopathology, digital pathology, and innovations such as organoid and Induced Pluripotent Stem Cell (iPSC) development, we enable both discovery and validation.
Our consultancy and advisory support ensure partners align with global biobanking standards. Research requests are integrated into Abu Dhabi’s Trusted Research Environment (TRE) for secure and ethical research access to drive public health advancement through regionally relevant research.
Every biospecimen is paired with powerful insights. By integrating clinical, demographic, and lifestyle data, we give researchers a 360-degree view of patient populations. Secure, de-identified databases are available through subscription or project-based access, enabling hypothesis generation and accelerating drug development through curated analytics. Our expertise propels partners to be at the forefront of a transformative effort that aligns with their strategic vision for a healthier, research-driven future for all.
We enable smarter, faster trials through patient stratification, pre-screening, and retrospective or prospective cohort design. Leveraging pan-human biospecimens, we help validate trial outcomes while advancing personalized medicine through companion diagnostic development in close collaboration with pharma partners. Our M42 network includes IROS, a UAE based CRO (Clinical Research Organization) with unparalleled access to cutting-edge scientific services and resources.
We aim to provide comprehensive and precise clinical solutions to drive healthcare and medical research excellence, focusing on real-world and clinical trial-backed evidence across all domains.
Trust is built on compliance. From informed consent management and donor engagement to advisory support for regulations like AABB, ISO, and EBAA submissions and others, we provide end-to-end ethical and regulatory guidance. Our expertise ensures international compliance, covering approvals, Material Transfer Agreements (MTAs), and legal frameworks with precision.
Our team of regulatory, legal and compliance experts helps clients contribute to global biomedical discovery and innovation.
Abu Dhabi Biobank is more than a repository—it’s your partner in accelerating the future of healthcare.